secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2023-01-12T23:59:59+00:00
Accession:  0001193125-23-007190
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences appoints David Gryska to board; Patricia Walker resigns
-------------------------------------------------------------------------

- David Gryska appointed as Class II director effective January 10, 2023; serves on Audit Committee.
- Gryska is former CFO/Exec VP of Incyte and Celgene; receives 50,000 stock option vesting over 3 years.
- Patricia Walker resigned from board and all committees effective January 6, 2023; no disagreement cited.
- Gryska will receive $40,000/year as director plus $8,000/year for Audit Committee service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312523007190/0001193125-23-007190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312523007190/d447019d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-007190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer